6 November 2008

Cyprotex PLC

(“Cyprotex“ or “the Company“)

Cyprotex PLC (LSE: CRX), the drug discovery services and information group, announces a trading update on its performance-to-date in calendar year to 2008.

Progress for the ten months to the end of October has been encouraging. The group produced a net profit in both the second and third quarters of 2008, and the Directors expect the same positive trend to continue into the fourth quarter. As a result the Directors expect 2008 full year net profits (including significant adjustments for non-recurring costs associated with the recent board restructuring) to be in excess of the current market expectations.

The Company announces that it will hold an investor call on 11th November 2008 at 16.30 (GMT). The call can be accessed by dialing into conference call telephone number: 0800-358-8171 and following the instructions to input pass code number: 329475 followed by #.

A presentation to accompany and support the call has been updated and will be available on the Company's website: www.cyprotex.com on the morning of the conference call.

For further information:

Cyprotex PLC
Dr Anthony Baxter, CEO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited
Charles Walker, Giles Balleny
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires
Pelham PR
Simon Miller
Tel: +44 (0)20 3178 4419
simon.miller@pelhampr.com